GTX-758 in treatment of prostate cancer

GTx has announced a second Phase I clinical trial evaluating GTx-758, an oral luteinizing hormone (LH) inhibitor (not an LHRH agonist or an LHRH antagonist), for first-line treatment of advanced prostate cancer.

A prior Phase I clinical trial in 96 subjects was completed in June.

The ongoing Phase I multiple ascending dose clinical trial will evaluate the safety, tolerability, and pharmacokinetic profile of GTx-758. In addition, clinical serum levels of testosterone and other hormones will be measured to assess the activity of GTx-758 on hormones secreted by the pituitary, hypothalamus, and adrenal glands.

GTx-758 is an oral LH inhibitor which is being developed for the treatment of advanced prostate cancer. Currently available data suggest that GTx-758 rapidly suppresses secretion of LH, thereby inhibiting production of androgens by the testes. GTx has stated trhat, in the company’s opinions, GTx-758 has the potential to reduce testosterone without causing bone loss and hot flashes.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: